Synagis (MedImmune Inc)
Synagis (MedImmune Inc) - General Information
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Synagis (MedImmune Inc) is expressed from a stable murine (mouse) myeloma cell line (NS0). Synagis (MedImmune Inc) is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Pharmacology of Synagis (MedImmune Inc)
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Synagis (MedImmune Inc) for patients
Synagis (MedImmune Inc) Interactions
No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of patients in the placebo and Synagis® groups who received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.
Synagis (MedImmune Inc) Contraindications
Synagis® should not be used in pediatric patients with a history of a severe prior reaction to Synagis® or other components of this product.
Additional information about Synagis (MedImmune Inc)
Synagis (MedImmune Inc) Indication: For treatment of respiratory diseases casued by respiratory syncytial virus
Mechanism Of Action: Binds to the outer coat or Fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Palivizumab
Synonyms: Synagis; anti-RSV
Drug Category: Antiviral Agents
Drug Type: Biotech; Approved
Other Brand Names containing Palivizumab: Synagis (MedImmune Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system.
Half Life: 18-20 days (in adults)
Dosage Forms of Synagis (MedImmune Inc): Powder, for solution Intramuscular
Chemical IUPAC Name: Humanized anti-RSV antibody
Chemical Formula: Not Available
Palivizumab on Wikipedia: https://en.wikipedia.org/wiki/Palivizumab
Organisms Affected: Not Available
